{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T11:20:37Z","timestamp":1787570437167,"version":"build-2736575974"},"reference-count":71,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Microorganisms"],"abstract":"<jats:p>Antimicrobial resistance (AMR) in Gram-negative pathogens represents a critical global health challenge. Combining cefepime with novel \u03b2-lactamase inhibitors (enmetazobactam, taniborbactam, zidebactam, and nacubactam) revitalizes the role of this fourth-generation cephalosporin in contemporary therapy. We present a narrative review according to the Scale for the Assessment of Narrative Review Articles (SANRA) criteria, summarizing the existing literature regarding new cefepime combinations with \u03b2-lactamase inhibitors. Based on 68 identified studies, data were structured by molecule. Each section explores in vitro activity, preclinical in vivo data, PK\/PD parameters, clinical evidence, and dosage. Findings demonstrate that these inhibitors successfully restore cefepime\u2019s efficacy against diverse resistance mechanisms, notably ESBLs, AmpC, KPC, OXA-48, and metallo-\u03b2-lactamases. \u201cCefepime 2.0\u201d therapies expand the therapeutic armamentarium against severe multidrug-resistant infections, offering vital carbapenem-sparing strategies. Because they possess distinct microbiological spectra, these agents serve complementary rather than interchangeable roles. Their clinical success demands targeted integration into antimicrobial stewardship programs to optimize efficacy and safely reduce carbapenem dependence.<\/jats:p>","DOI":"10.3390\/microorganisms14091875","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:07:53Z","timestamp":1787566073000},"page":"1875","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cefepime 2.0: Upgrading \u03b2-Lactamase Inhibitor Use"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8338-0130","authenticated-orcid":false,"given":"Francesco Giuseppe","family":"De Rosa","sequence":"first","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"},{"name":"Infectious Diseases, University Hospital Citt\u00e0 Della Salute e Della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3865-9519","authenticated-orcid":false,"given":"Tommaso","family":"Lupia","sequence":"additional","affiliation":[{"name":"Infectious Diseases, University Hospital Citt\u00e0 Della Salute e Della Scienza di Torino, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Fornari","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4353-8815","authenticated-orcid":false,"given":"Davide","family":"Vita","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7352-5353","authenticated-orcid":false,"given":"Marco","family":"Casarotto","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Corcione","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy"},{"name":"Division of Medicine, Tufts University School of Medicine, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0832-7975","authenticated-orcid":false,"given":"Alessandra","family":"Oliva","sequence":"additional","affiliation":[{"name":"Department of Public Health and Infectious Diseases, Sapienza University of Rome, 00185 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (WHO) (2024). Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report, World Health Organization."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"GBD 2021 Antimicrobial Resistance Collaborators (2024). Global burden of bacterial antimicrobial resistance 1990\u20132050: A systematic analysis. Lancet, 404, 1199\u20131226.","DOI":"10.1016\/S0140-6736(24)01885-3"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(07)70109-3","article-title":"Efficacy and safety of cefepime: A systematic review and meta-analysis","volume":"7","author":"Yahav","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s40262-022-01137-y","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Cefepime","volume":"61","author":"Pais","year":"2022","journal-title":"Clin. Pharmacokinet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1093\/jac\/dkaa511","article-title":"An update on cefepime and its future role in combination with novel \u03b2-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa","volume":"76","author":"Isler","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Papp-Wallace, K.M., Bethel, C.R., Caillon, J., Barnes, M.D., Potel, G., Bajaksouzian, S., Rutter, J.D., Reghal, A., Shapiro, S., and Taracila, M.A. (2019). Beyond piperacillin-tazobactam: Cefepime and AAI101 as a potent \u03b2-lactam-\u03b2-lactamase inhibitor combination. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00105-19"},{"key":"ref_7","unstructured":"(2026, July 13). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/exblifep."},{"key":"ref_8","unstructured":"US Food and Drug Administration (FDA) (2026, July 13). Drug Trials Snapshots: EXBLIFEP, Available online: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/drug-trials-snapshots-exblifep."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Morrissey, I., Magnet, S., Hawser, S., Shapiro, S., and Knechtle, P. (2019). In vitro activity of cefepime-enmetazobactam against Gram-negative isolates collected from U.S. and European hospitals during 2014\u20132015. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00514-19"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Henriksen, A.S., Arena, F., Attwood, M., Canton, R., Gatermann, S., Naas, T., Morrissey, I., Longshaw, C., ARTEMIS Study Investigators, and Willinger, B. (2024). In vitro activity of cefiderocol against European Enterobacterales, including isolates resistant to meropenem and recent \u03b2-lactam\/\u03b2-lactamase inhibitor combinations. Microbiol. Spectr., 12.","DOI":"10.1128\/spectrum.04181-23"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jmii.2021.08.012","article-title":"In vitro activity of cefiderocol, cefepime\/enmetazobactam, cefepime\/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018\u20132020","volume":"55","author":"Liu","year":"2022","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_12","unstructured":"US Food and Drug Administration (FDA) (2026, July 13). Antibacterial Susceptibility Test Interpretive Criteria, Available online: https:\/\/www.fda.gov\/drugs\/development-resources\/antibacterial-susceptibility-test-interpretive-criteria."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1128\/AAC.00033-15","article-title":"In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant gram-negative Enterobacteriaceae","volume":"59","author":"Crandon","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Bernhard, F., Odedra, R., Sordello, S., Cardin, R., Franzoni, S., Charrier, C., Belley, A., Warn, P., Machacek, M., and Knechtle, P. (2020). Pharmacokinetics-Pharmacodynamics of Enmetazobactam Combined with Cefepime in a Neutropenic Murine Thigh Infection Model. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.00078-20"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Principe, L., Lupia, T., Andriani, L., Campanile, F., Carcione, D., Corcione, S., De Rosa, F.G., Luzzati, R., Stroffolini, G., and Steyde, M. (2022). Microbiological, Clinical, and PK\/PD Features of the New Anti-Gram-Negative Antibiotics: \u03b2-Lactam\/\u03b2-Lactamase Inhibitors in Combination and Cefiderocol\u2014An All-Inclusive Guide for Clinicians. Pharmaceuticals, 15.","DOI":"10.3390\/ph15040463"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Johnson, A., McEntee, L., Farrington, N., Kolamunnage-Dona, R., Franzoni, S., Vezzelli, A., Massimiliano, M., Knechtle, P., Belley, A., and Dane, A. (2020). Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-\u03b2-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.00180-20"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Das, S., Fitzgerald, R., Ullah, A., Bula, M., Collins, A.M., Mitsi, E., Reine, J., Hill, H., Rylance, J., and Ferreira, D.M. (2021). Intrapulmonary pharmacokinetics of cefepime and enmetazobactam in healthy volunteers: Towards new treatments for nosocomial pneumonia. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.01468-20"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1001\/jama.2022.17034","article-title":"Effect of Cefepime\/Enmetazobactam vs Piperacillin\/Tazobactam on Clinical Cure and Microbiological Eradication in Patients with Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial","volume":"328","author":"Kaye","year":"2022","journal-title":"JAMA"},{"key":"ref_19","unstructured":"(2026, July 13). ClinicalTrials.gov. NCT03680352, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT03680352."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Karlowsky, J.A., Hackel, M.A., Wise, M.G., Six, D.A., Uehara, T., Daigle, D.M., Cusick, S.M., Pevear, D.C., Moeck, G., and Sahm, D.F. (2023). In Vitro Activity of Cefepime-Taniborbactam and Comparators against Clinical Isolates of Gram-Negative Bacilli from 2018 to 2020: Results from the Global Evaluation of Antimicrobial Resistance via Surveillance (GEARS) Program. Antimicrob. Agents Chemother., 67.","DOI":"10.1128\/aac.01281-22"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/jac\/dkac446","article-title":"In vivo pharmacokinetic\/pharmacodynamic evaluation of cefepime\/taniborbactam combination against cefepime-non-susceptible Enterobacterales and Pseudomonas aeruginosa in a murine pneumonia model","volume":"78","author":"Abdelraouf","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hernandez-Garcia, M., Garc\u00eda-Castillo, M., Ruiz-Garbajosa, P., Bou, G., Siller-Ruiz, M., Pitart, C., Gracia-Ahufinger, I., Mulet, X., Pascual, \u00c1., and Tormo, N. (2022). In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain. Antimicrob. Agents Chemother., 66.","DOI":"10.1128\/aac.02161-21"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Myers, C.L., Stevenson, A., Miller, B., Daigle, D.M., Uehara, T., and Pevear, D.C. (2025). Cefepime\u2013taniborbactam and ceftibuten\u2013ledaborbactam maintain activity against KPC variants that lead to ceftazidime\u2013avibactam resistance. Antimicrob. Agents Chemother., 69.","DOI":"10.1128\/aac.01511-24"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hamrick, J.C., Docquier, J.D., Uehara, T., Myers, C.L., Six, D.A., Chatwin, C.L., John, K.J., Vernacchio, S.F., Cusick, S.M., and Trout, R.E.L. (2020). VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine- And metallo-\u03b2-lactamases, restores activity of cefepime in enterobacterales and Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.01963-19"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1093\/jac\/dkad210","article-title":"Wide dissemination of Gram-negative bacteria producing the taniborbactam-resistant NDM-9 variant: A One Health concern","volume":"78","author":"Nordmann","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(23)00069-5","article-title":"NDM-9 resistance to taniborbactam","volume":"23","author":"Gruenig","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ono, D., Mojica, M.F., Bethel, C.R., Ishii, Y., Drusin, S.I., Moreno, D.M., Vila, A.J., and Bonomo, R.A. (2024). Structural role of K224 in taniborbactam inhibition of NDM-1. Antimicrob. Agents Chemother., 68.","DOI":"10.1128\/aac.01332-23"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Le Terrier, C., Freire, S., Viguier, C., Findlay, J., Nordmann, P., and Poirel, L. (2024). Relative inhibitory activities of the broad-spectrum \u03b2-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-\u03b2-lactamases produced in Escherichia coli and Pseudomonas aeruginosa. Antimicrob. Agents Chemother., 68.","DOI":"10.1128\/aac.00991-23"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jac\/dkac447","article-title":"Bronchopulmonary disposition of IV cefepime\/taniborbactam (2\u20130.5 g) administered over 2 h in healthy adult subjects","volume":"78","author":"Asempa","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Dowell, J.A., Dickerson, D., and Henkel, T. (2021). Safety and Pharmacokinetics in Human Volunteers of Taniborbactam (VNRX-5133), a Novel Intravenous \u03b2-Lactamase Inhibitor. Antimicrob. Agents Chemother., 65.","DOI":"10.1128\/AAC.01053-21"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Dowell, J.A., Marbury, T.C., and Smith, W.B. (2022). Safety and Pharmacokinetics of Taniborbactam (VNRX-5133) with Cefepime in Subjects with Various Degrees of Renal Impairment. Antimicrob. Agents Chemother., 66.","DOI":"10.1128\/aac.00253-22"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1056\/NEJMoa2304748","article-title":"Cefepime\u2013Taniborbactam in Complicated Urinary Tract Infection","volume":"390","author":"Wagenlehner","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_33","unstructured":"(2026, July 13). ClinicalTrialsgov Study Details|Cefepime-Taniborbactam vs. Meropenem in Adults with VABP or Ventilated HABP (CERTAIN-2), Available online: https:\/\/clinicaltrials.gov\/study\/NCT06168734."},{"key":"ref_34","unstructured":"(2026, July 13). Venatorx Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam. Available online: https:\/\/venatorx.com\/press-releases\/venatorx-and-melinta-provide-update-on-status-of-u-s-new-drug-application-for-cefepime-taniborbactam\/."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/jac\/dkw593","article-title":"In vitro activity of cefepime\/zidebactam (WCK 5222) against Gram-negative bacteria","volume":"72","author":"Livermore","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Moya, B., Barcelo, I.M., Bhagwat, S., Patel, M., Bou, G., Papp-Wallace, K.M., Bonomo, R.A., and Oliver, A. (2017). Potent \u00df-lactam enhancer activity of zidebactam and WCK 5153 against Acinetobacter baumannii, including carbapenemase-producing clinical isolates. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.01238-17"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1093\/jac\/dkx050","article-title":"WCK 5222 (cefepime\/zidebactam) antimicrobial activity tested against Gram-negative organisms producing clinically relevant \u03b2-lactamases","volume":"72","author":"Sader","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmii.2025.01.006","article-title":"Antimicrobial resistance among imipenem-non-susceptible Escherichia coli and Klebsiella pneumoniae isolates, with an emphasis on novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and tetracycline derivatives: The Taiwan surveillance of antimicrobial resis","volume":"58","author":"Lee","year":"2025","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"116561","DOI":"10.1016\/j.diagmicrobio.2024.116561","article-title":"In vitro activity of zidebactam\/cefepime (WCK 5222), a \u03b2-lactam enhancer\/\u03b2-lactam combination against carbapenem- and colistin-resistant Klebsiella pneumoniae isolates","volume":"111","author":"Bakthavatchalam","year":"2025","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1093\/jac\/dkaf045","article-title":"Decreased susceptibility to cefepime\/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2","volume":"80","author":"Tellapragada","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Avery, L.M., Abdelraouf, K., and Nicolau, D.P. (2018). Assessment of the in vivo efficacy of WCK 5222 (Cefepime-Zidebactam) against carbapenem-resistant acinetobacter baumannii in the neutropenic murine lung infection model. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00948-18"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Almarzoky Abuhussain, S.S., Avery, L.M., Abdelraouf, K., and Nicolau, D.P. (2019). In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01931-18"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Monogue, M.L., Tabor-Rennie, J., Abdelraouf, K., and Nicolau, D.P. (2019). In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Multidrug-Resistant Pseudomonas aeruginosa in the Neutropenic Murine Thigh Infection Model. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.00233-19"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Lepak, A.J., Zhao, M., and Andes, D.R. (2019). WCK 5222 (cefepime-zidebactam) pharmacodynamic target analysis against metallo-\u03b2-lactamase-producing Enterobacteriaceae in the neutropenic mouse pneumonia model. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01648-19"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Bhagwat, S.S., Periasamy, H., Takalkar, S.S., Palwe, S.R., Khande, H.N., and Patel, M.V. (2019). The Novel -Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.02146-18"},{"key":"ref_46","unstructured":"ClinicalTrials.gov (2026, July 13). Study Details|MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02674347."},{"key":"ref_47","unstructured":"ClinicalTrials.gov (2026, July 13). Study Details|MED Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous WCK 5222 (Zidebactam and Cefepime) in Healthy Volunteers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02707107."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Rodvold, K.A., Gotfried, M.H., Chugh, R., Gupta, M., Patel, A., Chavan, R., Yeole, R., Friedland, H.D., and Bhatia, A. (2018). Plasma and intrapulmonary concentrations of cefepime and zidebactam following intravenous administration of wck 5222 to healthy adult subjects. Antimicrob. Agents Chemother., 62.","DOI":"10.1128\/AAC.00682-18"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Preston, R.A., Mamikonyan, G., DeGraff, S., Chiou, J., Kemper, C.J., Xu, A., Mastim, M., Yeole, R., Chavan, R., and Patel, A. (2019). Single-center evaluation of the pharmacokinetics of WCK 5222 (cefepime-zidebactam combination) in subjects with renal impairment. Antimicrob. Agents Chemother., 63.","DOI":"10.1128\/AAC.01484-18"},{"key":"ref_50","unstructured":"ClinicalTrials.gov (2026, July 13). Study Details|Study of Cefepime-Zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP), Available online: https:\/\/clinicaltrials.gov\/study\/NCT04979806."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/trstmh\/trae049","article-title":"Difficult to treat Pseudomonas: Successful salvage therapy with cefepime-zidebactam","volume":"118","author":"Sebastian","year":"2024","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Soman, R., Sirsat, R., Sunavala, A., Punatar, N., Mehta, J., Rodrigues, C., and Veeraraghavan, B. (2024). Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-\u03b2-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime\/zidebactam (WCK 5222). Eur. J. Clin. Microbiol. Infect. Dis.","DOI":"10.1007\/s10096-024-04791-1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12941-023-00606-x","article-title":"Compassionate use of a novel \u03b2-lactam enhancer-based investigational antibiotic cefepime\/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: A case report","volume":"22","author":"Dubey","year":"2023","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1093\/jac\/dkv166","article-title":"OP0595, a new diazabicyclooctane: Mode of action as a serine \u03b2-lactamase inhibitor, antibiotic and \u03b2-lactam \u2018enhancer\u2019","volume":"70","author":"Morinaka","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/jac\/dky522","article-title":"Activity of nacubactam (RG6080\/OP0595) combinations against MBL-producing enterobacteriaceae","volume":"74","author":"Mushtaq","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1007\/s11095-023-03608-8","article-title":"In vivo Pharmacokinetic\/Pharmacodynamic Analysis of the Efficacy of the Cefepime\/Nacubactam Combination Against \u03b2-Lactamase-Producing Enterobacterales based on the Instantaneous MIC Concept","volume":"40","author":"Igarashi","year":"2023","journal-title":"Pharm. Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Sader, H.S., Kimbrough, J.H., Winkler, M.L., Mendes, R.E., and Castanheira, M. (2025). Activity of \u03b2-Lactamase Inhibitor Combinations Against Enterobacterales Isolated from Patients with Intra-Abdominal Infection from United States Medical Centres (2019\u20132023). Antibiotics, 14.","DOI":"10.3390\/antibiotics14060544"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.2147\/IDR.S314241","article-title":"An evidence-based multidisciplinary approach focused at creating algorithms for targeted therapy of bsis, cutis, and ciais caused by enterobacterales in critically ill adult patients","volume":"14","author":"Gatti","year":"2021","journal-title":"Infect. Drug Resist."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Kaku, N., Kosai, K., Takeda, K., Uno, N., Morinaga, Y., Hasegawa, H., Miyazaki, T., Izumikawa, K., Mukae, H., and Yanagihara, K. (2017). Efficacy and Pharmacokinetics of the Combination of OP0595 and Cefepime in a Mouse Model of Pneumonia Caused by Extended-Spectrum-Beta-Lactamase-Producing Klebsiella pneumoniae. Antimicrob. Agents Chemother., 61.","DOI":"10.1128\/AAC.00828-17"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Hagihara, M., Kato, H., Sugano, T., Okade, H., Sato, N., Shibata, Y., Sakanashi, D., Hirai, J., Asai, N., and Suematsu, H. (2021). In vivo pharmacodynamics of \u03b2-lactams\/nacubactam against carbapenem-resistant and\/or carbapenemase-producing enterobacter cloacae and klebsiella pneumoniae in murine pneumonia model. Antibiotics, 10.","DOI":"10.3390\/antibiotics10101179"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jac\/dkae443","article-title":"Simulated achievement rate of \u03b2-lactams\/nacubactam treatment in humans using instantaneous MIC-based PK\/PD analysis","volume":"80","author":"Igarashi","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Mallalieu, N.L., Winter, E., Fettner, S., Patel, K., Zwanziger, E., Attley, G., Rodriguez, I., Kano, A., Salama, S.M., and Bentley, D. (2020). Safety and pharmacokinetic characterization of nacubactam, a novel \u03b2-lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers. Antimicrob. Agents Chemother., 64.","DOI":"10.1128\/AAC.02229-19"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S539","DOI":"10.1093\/ofid\/ofz360.1341","article-title":"A Randomized Phase 2 Study of Cefepime Combined with the Novel Extended Spectrum \u03b2-Lactamase Inhibitor Enmetazobactam in Hospitalized Adults with Complicated Urinary Tract Infections (cUTI) Including Acute Pyelonephritis (AP)","volume":"6","author":"Carmeli","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_64","unstructured":"ClinicalTrials.gov (2026, July 13). Study Details|Efficacy and Safety of Cefepime\/Nacubactam or Aztreonam\/Nacubactam Compared to Imipenem\/Cilastatin in Subjects with Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05887908."},{"key":"ref_65","unstructured":"ClinicalTrials.gov (2026, July 13). Study Details|P3 Study to Assess Efficacy and Safety of Cefepime\/Nacubactam and Aztreonam\/Nacubactam Versus Best Available Therapy for Adults with Infection Due to Carbapenem Resistant Enterobacterales, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05905055."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients with E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): A randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1093\/jac\/dkad280","article-title":"Efficacy and safety of ceftazidime\/avibactam in patients with infections caused by \u03b2-lactamase-producing Gram-negative pathogens: A pooled analysis from the Phase 3 clinical trial programme","volume":"78","author":"Torres","year":"2023","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/jac\/25.6.959","article-title":"Cefepime concentrations in bronchial mucosa and serum following a single 2 gram intravenous dose","volume":"25","author":"Chadha","year":"1990","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_71","first-page":"149","article-title":"Efficacy of human-simulated bronchopulmonary exposures of cefepime, zidebactam and the combination (WCK 5222) against MDR Pseudomonas aeruginosa in a neutropenic murine pneumonia model","volume":"75","author":"Kidd","year":"2020","journal-title":"J. Antimicrob. Chemother."}],"container-title":["Microorganisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/9\/1875\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T10:30:27Z","timestamp":1787567427000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-2607\/14\/9\/1875"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":71,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["microorganisms14091875"],"URL":"https:\/\/doi.org\/10.3390\/microorganisms14091875","relation":{},"ISSN":["2076-2607"],"issn-type":[{"value":"2076-2607","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}